---
// src/pages/science/genetics.astro
import BaseLayout from "../../layouts/BaseLayout.astro";
import { useTranslations } from "../../i18n";

const t = useTranslations('en');
---

<BaseLayout 
  title={t.sections.genetics.title}
  description="Genetic factors in post-vaccination narcolepsy: HLA associations, B3GALT4 variants, and GT1B regulation."
>
  <section class="bg-gradient-to-b from-slate-900 to-slate-800 text-white py-16">
    <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
      <nav class="text-sm text-slate-400 mb-4">
        <a href="/" class="hover:text-white transition-colors">Home</a>
        <span class="mx-2">/</span>
        <a href="/science/" class="hover:text-white transition-colors">Science</a>
        <span class="mx-2">/</span>
        <span class="text-white">Genetics</span>
      </nav>
      <h1 class="text-4xl md:text-5xl font-bold mb-4">{t.sections.genetics.title}</h1>
      <p class="text-xl text-slate-300 max-w-3xl">
        {t.sections.genetics.subtitle}
      </p>
    </div>
  </section>

  <section class="py-12">
    <div class="max-w-4xl mx-auto px-4 sm:px-6 lg:px-8">
      <div class="prose-science">
        
        <h2>HLA-DQB1*06:02 Association</h2>
        <p>
          Virtually all cases of Pandemrix-associated narcolepsy occur in individuals carrying 
          the HLA-DQB1*06:02 allele. This strong genetic association has been interpreted as 
          evidence for autoimmune etiology ‚Äî HLA molecules present antigens to T cells, and 
          DQB1*06:02 may efficiently present H1N1-derived peptides that cross-react with 
          orexin receptor epitopes.
        </p>

        <div class="key-concept">
          <div class="key-concept-title">Block Inheritance ‚Äî The Critical Point</div>
          <p class="mb-0">
            HLA genes are inherited in blocks (haplotypes). The DQB1*06:02 allele is in strong 
            linkage disequilibrium with many nearby genes. <strong>Critically, the ganglioside 
            synthesis gene B3GALT4 is located at 6p21.32 ‚Äî directly within the HLA region.</strong> 
            The true susceptibility gene may not be DQB1*06:02 itself, but B3GALT4 or another linked variant.
          </p>
        </div>

        <h2>The B3GALT4 Connection ‚Äî Key Discovery</h2>
        <p>
          <span class="gene-name">B3GALT4</span> (Beta-1,3-galactosyltransferase 4) is located on 
          <strong>Chromosome 6p21.32</strong> ‚Äî the same chromosomal band as the HLA complex. 
          This gene encodes the enzyme that catalyzes a critical step in GT1b biosynthesis:
        </p>
        
        <div class="bg-slate-100 rounded-lg p-4 my-6 font-mono text-sm">
          GD2 ‚Üí <span class="text-red-600 font-bold">GD1b</span> ‚Üí GT1b
          <br/>
          <span class="text-slate-500">‚Üë B3GALT4 adds galactose here</span>
        </div>

        <p>
          This is potentially the most important genetic finding for this hypothesis:
        </p>
        <ul>
          <li>B3GALT4 is <strong>essential</strong> for GT1b production</li>
          <li>It lies in the <strong>same chromosomal region</strong> as HLA-DQB1</li>
          <li>Variants affecting B3GALT4 expression could directly alter GT1b levels in neurons</li>
          <li>The apparent "HLA association" may actually be a <strong>B3GALT4 association</strong></li>
        </ul>

        <div class="warning-box">
          <h4 class="font-bold text-amber-800 mb-2">Reinterpreting the HLA Association</h4>
          <p class="text-amber-700 text-sm mb-0">
            If narcolepsy susceptibility is driven by B3GALT4 variants (affecting GT1b synthesis) 
            rather than HLA-DQB1*06:02 (affecting antigen presentation), this fundamentally changes 
            our understanding of the mechanism. The disease would be primarily a disorder of 
            <em>ganglioside-mediated transport</em> rather than <em>HLA-mediated autoimmunity</em> ‚Äî 
            though autoimmunity remains the downstream effector.
          </p>
        </div>

        <h2>Chromosome 6p21.3 ‚Äî The Narcolepsy Region</h2>
        <p>
          The 6p21.3 region contains both the HLA complex and critical ganglioside-regulatory genes. 
          <strong>A key insight:</strong> Three genes are inherited together in the same haplotype 
          (linkage disequilibrium block), creating a "synergistic trinity" that may explain susceptibility.
        </p>

        <!-- Chromosome 6 Map -->
        <figure class="my-8">
          <img 
            src="/images/chromosome6-gene-map.svg" 
            alt="Chromosome 6p21 gene map showing physical positions of NEU1 (31.86 Mb), HLA-DQB1 (32.66 Mb), and B3GALT4 (33.28 Mb)"
            class="w-full rounded-lg border border-slate-700 shadow-lg"
          />
          <figcaption class="text-sm text-slate-600 mt-3 text-center">
            <strong>Physical map of chromosome 6p21:</strong> NEU1 (sialidase) and B3GALT4 (GT1b synthase) 
            flank the HLA-DQB1 locus. All three are inherited together due to strong linkage disequilibrium.
          </figcaption>
        </figure>
        
        <table class="w-full text-sm">
          <thead>
            <tr class="border-b bg-slate-50">
              <th class="text-left py-2 px-2">Gene</th>
              <th class="text-left py-2 px-2">Location</th>
              <th class="text-left py-2 px-2">Function</th>
              <th class="text-left py-2 px-2">Role in Hypothesis</th>
            </tr>
          </thead>
          <tbody>
            <tr class="border-b bg-cyan-50">
              <td class="py-2 px-2"><span class="gene-name">NEU1</span></td>
              <td class="py-2 px-2 font-bold text-cyan-700">6p21.33</td>
              <td class="py-2 px-2">Neuraminidase 1 (sialidase)</td>
              <td class="py-2 px-2"><strong>KEY</strong> ‚Äî Regulates TLR activation, removes sialic acid</td>
            </tr>
            <tr class="border-b bg-purple-50">
              <td class="py-2 px-2"><span class="gene-name">HLA-DQB1</span></td>
              <td class="py-2 px-2 font-bold text-purple-700">6p21.32</td>
              <td class="py-2 px-2">MHC class II</td>
              <td class="py-2 px-2"><strong>ANCHOR</strong> ‚Äî Antigen presentation</td>
            </tr>
            <tr class="border-b bg-amber-50">
              <td class="py-2 px-2"><span class="gene-name">B3GALT4</span></td>
              <td class="py-2 px-2 font-bold text-amber-700">6p21.32</td>
              <td class="py-2 px-2">GM1/GD1b synthase</td>
              <td class="py-2 px-2"><strong>KEY</strong> ‚Äî Creates GD1b, precursor to GT1b</td>
            </tr>
          </tbody>
        </table>

        <!-- NEW SECTION: NEU1 -->
        <h2>NEU1 ‚Äî A Candidate for Neuroinflammatory Involvement?</h2>
        
        <div class="key-concept">
          <div class="key-concept-title">NEU1: Proximity to HLA ‚Äî But What Role?</div>
          <p class="mb-0">
            <span class="gene-name">NEU1</span> (Neuraminidase 1) is a lysosomal sialidase that removes terminal sialic acids 
            from <strong>N-glycans on glycoproteins</strong> (NOT gangliosides like GT1b). It lies at <strong>6p21.33</strong> ‚Äî 
            within the same haplotype block as HLA-DQB1*06:02. While NEU1 is <em>not</em> a confirmed GWAS hit for narcolepsy, 
            its location in the MHC region and its role in <strong>neuroinflammation</strong> (analogous to Alzheimer's disease) 
            make it a speculative but interesting candidate.
          </p>
        </div>

        <h3>The N-Glycan Finding: What Does It Really Show?</h3>
        <p>
          Mass spectrometry studies (Sanni et al., ACS Omega 2024) show that NT1 patients have a 
          <strong>~3-fold increase in trisialylated N-glycans</strong>. However, the finding is more nuanced than it first appears:
        </p>

        <div class="bg-amber-50 border border-amber-200 rounded-lg p-6 my-6">
          <h4 class="font-bold text-amber-800 mb-4">The Actual Data ‚Äî Context Matters</h4>
          
          <table class="w-full text-sm mb-4">
            <thead>
              <tr class="border-b bg-amber-100">
                <th class="text-left py-2 px-2 text-amber-800">Glycan Type</th>
                <th class="text-left py-2 px-2 text-amber-800">Controls</th>
                <th class="text-left py-2 px-2 text-amber-800">NT1 Patients</th>
                <th class="text-left py-2 px-2 text-amber-800">Change</th>
              </tr>
            </thead>
            <tbody>
              <tr class="border-b">
                <td class="py-2 px-2">Monosialylated</td>
                <td class="py-2 px-2">~25%</td>
                <td class="py-2 px-2">~25-26%</td>
                <td class="py-2 px-2 text-slate-500">No change</td>
              </tr>
              <tr class="border-b">
                <td class="py-2 px-2">Disialylated</td>
                <td class="py-2 px-2">~32%</td>
                <td class="py-2 px-2">~32-33%</td>
                <td class="py-2 px-2 text-slate-500">No change</td>
              </tr>
              <tr class="border-b bg-cyan-50">
                <td class="py-2 px-2 font-medium text-cyan-800">Trisialylated</td>
                <td class="py-2 px-2 text-cyan-800">~0.75%</td>
                <td class="py-2 px-2 text-cyan-800 font-bold">~2.2%</td>
                <td class="py-2 px-2 text-cyan-800 font-bold">~3x increase ‚úì</td>
              </tr>
            </tbody>
          </table>
          
          <p class="text-amber-800 text-sm mb-0">
            <strong>Key insight:</strong> The ~3-fold increase is real and statistically significant, but trisialylated 
            glycans remain a <strong>small fraction</strong> (~2%) of total glycans. This is a <em>specific</em> change, 
            not a dramatic shift in overall sialylation.
          </p>
        </div>

        <div class="warning-box">
          <h4 class="font-bold text-amber-800 mb-2">‚ö†Ô∏è Critical Clarification: NEU1 Does NOT Act on GT1b</h4>
          <p class="text-amber-700 text-sm mb-2">
            <strong>NEU1</strong> primarily degrades <strong>N-glycans on glycoproteins</strong>, NOT gangliosides like GT1b.
          </p>
          <table class="w-full text-xs mb-2">
            <tr class="border-b">
              <td class="py-1 font-bold">NEU1</td>
              <td class="py-1">Lysosomal ‚Üí N-glycans, oligosaccharides</td>
            </tr>
            <tr class="border-b">
              <td class="py-1 font-bold">NEU3</td>
              <td class="py-1">Plasma membrane ‚Üí Gangliosides (GT1b, GD1a, GM1)</td>
            </tr>
            <tr>
              <td class="py-1 font-bold">NEU4</td>
              <td class="py-1">Mitochondria/ER ‚Üí Gangliosides</td>
            </tr>
          </table>
          <p class="text-amber-700 text-sm mb-0">
            <strong>Implication:</strong> A "Lazy NEU1" could explain the N-glycan finding, but would <em>not</em> directly 
            cause GT1b accumulation. If GT1b accumulation is relevant, we should look at <strong>NEU3 or NEU4</strong>, not NEU1.
          </p>
        </div>

        <h3>The "Lazy Enzyme" Model ‚Äî A Possible Explanation for N-Glycans</h3>
        <div class="grid md:grid-cols-2 gap-4 my-6">
          <div class="bg-slate-100 rounded p-4 border border-slate-200">
            <h5 class="font-bold text-slate-700 mb-2">Normal NEU1</h5>
            <ul class="text-slate-700 text-sm space-y-1">
              <li>‚Ä¢ Efficiently removes sialic acids from N-glycans</li>
              <li>‚Ä¢ Trisialylated N-glycans are properly degraded</li>
              <li>‚Ä¢ Serum glycoproteins have normal sialylation</li>
            </ul>
          </div>
          <div class="bg-cyan-50 rounded p-4 border border-cyan-200">
            <h5 class="font-bold text-cyan-700 mb-2">NEU1 "Lazy Enzyme" (Hypothesis)</h5>
            <ul class="text-slate-700 text-sm space-y-1">
              <li>‚Ä¢ Reduced sialidase activity on N-glycans</li>
              <li>‚Ä¢ Trisialylated N-glycans accumulate (~3x increase)</li>
              <li>‚Ä¢ <em>Could</em> explain the serum finding in NT1</li>
            </ul>
          </div>
        </div>

        <div class="info-box">
          <h4 class="font-bold text-blue-800 mb-2">What About GT1b?</h4>
          <p class="text-blue-700 text-sm mb-0">
            The N-glycan finding is <strong>separate</strong> from the GT1b hypothesis. NEU1 acts on N-glycans (glycoproteins), 
            while GT1b is a ganglioside degraded by <strong>NEU3/NEU4</strong>. If GT1b accumulation is the mechanism 
            for increased viral binding, we would need to look for variants in <em>NEU3</em> or <em>NEU4</em>, which lie 
            on <strong>different chromosomes</strong> (11q13 and 2q37, respectively) ‚Äî not in the MHC region.
          </p>
        </div>

        <!-- NEW: Alzheimer's Analogy Section -->
        <h3>An Alternative Hypothesis: NEU1 and Neuroinflammation</h3>
        <p>
          While NEU1 does not act on gangliosides, there is another pathway by which it <em>could</em> contribute 
          to orexin neuron death ‚Äî via <strong>neuroinflammation and immune dysregulation</strong>. This hypothesis 
          draws on analogies from Alzheimer's disease research.
        </p>

        <div class="bg-purple-50 border border-purple-200 rounded-lg p-6 my-6">
          <h4 class="font-bold text-purple-800 mb-4">The Alzheimer's Disease Analogy</h4>
          <p class="text-purple-700 text-sm mb-3">
            In Alzheimer's disease, <strong>NEU1 deficiency</strong> has been shown to drive neurodegeneration:
          </p>
          <ul class="text-purple-700 text-sm space-y-1 mb-3">
            <li>‚Ä¢ NEU1 ‚Üì ‚Üí Hypersialylation of glycoproteins</li>
            <li>‚Ä¢ Hypersialylation ‚Üí Lysosomal dysfunction</li>
            <li>‚Ä¢ Lysosomal dysfunction ‚Üí Neuroinflammation (microglia activation)</li>
            <li>‚Ä¢ Neuroinflammation ‚Üí Neuronal death</li>
          </ul>
          <p class="text-purple-700 text-sm mb-0">
            <strong>Key finding:</strong> In AD models, <em>increasing</em> NEU1 activity is <strong>protective</strong>, 
            while NEU1 deficiency accelerates neurodegeneration. Could a similar mechanism apply to orexin neurons?
          </p>
        </div>

        <div class="key-concept">
          <div class="key-concept-title">Hypothesis: NEU1 ‚Üí Hypersialylation ‚Üí Orexin Death</div>
          <p class="mb-2">
            <em>If</em> NEU1 is underactive in NT1 patients, hypersialylation of glycoproteins on or around 
            orexin neurons could contribute to their destruction via several mechanisms:
          </p>
          <ol class="text-sm space-y-2 mb-0">
            <li><strong>1. Altered immune recognition:</strong> Hypersialylated cell surfaces may be recognized 
            as "foreign" by autoreactive T-cells, especially in the context of HLA-DQB1*06:02 antigen presentation.</li>
            <li><strong>2. Neuroinflammation:</strong> Hypersialylation disrupts lysosomal clearance and activates 
            microglia/macrophages, creating a pro-inflammatory environment around orexin neurons.</li>
            <li><strong>3. Disrupted immune tolerance:</strong> Sialylation normally masks antigens from the immune 
            system; abnormal sialylation patterns could disrupt this tolerance and facilitate autoimmune attack.</li>
          </ol>
        </div>

        <div class="warning-box">
          <h4 class="font-bold text-amber-800 mb-2">‚ö†Ô∏è Important: This Is Speculative</h4>
          <p class="text-amber-700 text-sm mb-2">
            <strong>No study has directly tested</strong> NEU1 expression in orexin neurons or the hypothalamus of NT1 patients. 
            This hypothesis is based on:
          </p>
          <ul class="text-amber-700 text-sm mb-2">
            <li>‚Ä¢ The N-glycan finding (hypersialylation in NT1 serum)</li>
            <li>‚Ä¢ NEU1's location in the MHC region (linkage disequilibrium with HLA-DQB1*06:02)</li>
            <li>‚Ä¢ Analogies from Alzheimer's disease research</li>
          </ul>
          <p class="text-amber-700 text-sm mb-0">
            <strong>To test this hypothesis:</strong> Measure NEU1 activity/levels in post-mortem hypothalamus from NT1 patients; 
            analyze sialylation of hypocretin-related proteins; test animal models with NEU1 knockdown + autoimmune trigger.
          </p>
        </div>

        <div class="warning-box">
          <h4 class="font-bold text-amber-800 mb-2">The Sialidosis Paradox</h4>
          <p class="text-amber-700 text-sm mb-0">
            Complete NEU1 loss causes <strong>Sialidosis</strong> (lysosomal storage disease with severe symptoms). 
            NT1 patients don't have Sialidosis, so the NEU1 variant must be <em>subtle</em> ‚Äî affecting regulation 
            or membrane translocation rather than complete enzyme loss. This "sub-clinical" defect creates 
            susceptibility without overt disease.
          </p>
        </div>

        <!-- Dual-Hit Hypothesis Diagram -->
        <h2>The Dual-Hit Hypothesis: Synergistic Enzyme Variants</h2>
        <p>
          We propose that the risk haplotype carries <em>two</em> enzyme variants that synergize:
        </p>

        <figure class="my-8">
          <img 
            src="/images/dual-hit-hypothesis.svg" 
            alt="Dual-Hit Hypothesis: B3GALT4 gain-of-function creates more GT1b targets, NEU1 regulation defect removes immune brakes"
            class="w-full rounded-lg border border-slate-200 shadow-lg bg-white"
          />
          <figcaption class="text-sm text-slate-600 mt-3 text-center">
            <strong>The Dual-Hit Hypothesis:</strong> B3GALT4 overproduction creates more GT1b "fuel" for viral binding, 
            while NEU1 dysfunction removes the immune system's "brakes," leading to uncontrolled inflammation.
          </figcaption>
        </figure>

        <div class="bg-slate-800 text-white rounded-lg p-6 my-6">
          <h4 class="font-bold text-cyan-400 mb-4">Genetic Candidates ‚Äî What's Confirmed vs. Hypothesized</h4>
          <table class="w-full text-sm">
            <thead>
              <tr class="border-b border-slate-600">
                <th class="text-left py-2 text-slate-300">Gene</th>
                <th class="text-left py-2 text-slate-300">Status</th>
                <th class="text-left py-2 text-slate-300">Hypothesized Mechanism</th>
              </tr>
            </thead>
            <tbody>
              <tr class="border-b border-slate-700">
                <td class="py-2 text-purple-400 font-bold">HLA-DQB1*06:02</td>
                <td class="py-2 text-green-400">‚úì Confirmed</td>
                <td class="py-2 text-slate-300">Antigen presentation ‚Äî presents mimicry peptides to T cells</td>
              </tr>
              <tr class="border-b border-slate-700">
                <td class="py-2 text-cyan-400 font-bold">NEU1</td>
                <td class="py-2 text-yellow-400">? Hypothesis</td>
                <td class="py-2 text-slate-300"><em>If</em> underactive ‚Üí hypersialylation ‚Üí neuroinflammation ‚Üí orexin death (Alzheimer's analogy)</td>
              </tr>
              <tr>
                <td class="py-2 text-amber-400 font-bold">B3GALT4</td>
                <td class="py-2 text-yellow-400">? Hypothesis</td>
                <td class="py-2 text-slate-300"><em>If</em> overactive ‚Üí increased GT1b production ‚Üí viral binding sites</td>
              </tr>
            </tbody>
          </table>
          <p class="text-slate-400 text-xs mt-3 italic">
            <strong>Note:</strong> NEU1 acts on N-glycans (NOT GT1b). Its potential role is via neuroinflammation, 
            analogous to mechanisms seen in Alzheimer's disease ‚Äî not ganglioside metabolism.
          </p>
        </div>

        <!-- How Both Pathways Could Lead to More GT1b -->
        <h2>Hypothetical Pathways: How GT1b Could Accumulate</h2>
        
        <div class="warning-box mb-6">
          <h4 class="font-bold text-amber-800 mb-2">‚ö†Ô∏è Important: This Is a Hypothesis</h4>
          <p class="text-amber-700 text-sm mb-0">
            <strong>No study has yet confirmed</strong> that NT1 patients carry "Lazy Enzyme" (NEU1) or 
            "Super-Enzyme" (B3GALT4) variants. These are <em>proposed mechanisms</em> that could explain 
            the observed N-glycan elevation ‚Äî but remain to be tested. The proximity of these genes to 
            HLA-DQB1 makes them compelling candidates for future research.
          </p>
        </div>

        <p>
          <em>If</em> functional variants exist in either NEU1 or B3GALT4, they could theoretically lead 
          to <strong>increased GT1b on nerve surfaces</strong> via two different mechanisms:
        </p>

        <div class="grid md:grid-cols-2 gap-6 my-8">
          <div class="bg-cyan-50 border border-cyan-200 rounded-lg p-6">
            <h4 class="font-bold text-cyan-800 mb-3">Hypothesis A: NEU1 "Lazy Enzyme"</h4>
            <div class="text-center mb-3">
              <span class="text-4xl">üîΩ</span>
              <p class="text-cyan-700 text-sm font-bold">Reduced Degradation</p>
            </div>
            <p class="text-cyan-700 text-sm">
              NEU1 normally breaks down gangliosides by removing sialic acids. 
              <em>If</em> a variant reduces its activity, GT1b would accumulate on nerve surfaces.
            </p>
            <div class="bg-white rounded p-3 mt-3 text-center">
              <p class="text-cyan-800 font-mono text-sm">GT1b breakdown ‚Üì ‚Üí GT1b levels ‚Üë</p>
            </div>
            <p class="text-cyan-600 text-xs mt-2 italic">
              <strong>Supporting evidence:</strong> 3x elevated trisialylated N-glycans in NT1 patients 
              suggests reduced sialidase activity.
            </p>
          </div>
          
          <div class="bg-amber-50 border border-amber-200 rounded-lg p-6">
            <h4 class="font-bold text-amber-800 mb-3">Hypothesis B: B3GALT4 "Super-Enzyme"</h4>
            <div class="text-center mb-3">
              <span class="text-4xl">üîº</span>
              <p class="text-amber-700 text-sm font-bold">Increased Production</p>
            </div>
            <p class="text-amber-700 text-sm">
              B3GALT4 synthesizes the GT1b precursor GD1b. <em>If</em> a variant increases its activity, 
              more GT1b would be produced than can be shed via exosomes.
            </p>
            <div class="bg-white rounded p-3 mt-3 text-center">
              <p class="text-amber-800 font-mono text-sm">GT1b production ‚Üë ‚Üí GT1b levels ‚Üë</p>
            </div>
            <p class="text-amber-600 text-xs mt-2 italic">
              <strong>Supporting rationale:</strong> B3GALT4 lies within the MHC region, in LD with HLA-DQB1.
            </p>
          </div>
        </div>

        <div class="key-concept">
          <div class="key-concept-title">The "Double-Hit" Hypothesis</div>
          <p class="mb-0">
            <em>If</em> both variants exist in the risk haplotype, they could synergize: NEU1 underactivity 
            would reduce degradation, while B3GALT4 overactivity would increase production. The combined effect 
            <em>could</em> be a significant increase in GT1b on peripheral nerve surfaces ‚Äî creating more 
            binding sites for H1N1 antigen. <strong>This remains to be tested.</strong>
          </p>
        </div>

        <h2>GT1b Exosome Shedding: Why No Storage Disease?</h2>
        <p>
          A critical question: if B3GALT4 overproduces GT1b, why don't patients develop a storage disease 
          like Tay-Sachs? The answer lies in the <strong>distinction between storage and secretion</strong>.
        </p>

        <figure class="my-8">
          <img 
            src="/images/gt1b-exosome-shedding.svg" 
            alt="Comparison between lysosomal storage disease and GT1b exosome shedding"
            class="w-full rounded-lg border border-slate-200 shadow-lg bg-white"
          />
          <figcaption class="text-sm text-slate-600 mt-3 text-center">
            <strong>Storage vs Shedding:</strong> In storage diseases (left), enzyme deficiency causes 
            intracellular accumulation and cell death. In super-enzyme overproduction (right), excess GT1b 
            is SHED via exosomes, keeping the cell healthy but creating an extracellular inflammatory environment.
          </figcaption>
        </figure>

        <div class="key-concept">
          <div class="key-concept-title">GT1b Exosomes as Endogenous Adjuvants</div>
          <p class="mb-0">
            Research shows that extracellular GT1b directly activates <strong>TLR2</strong> and induces 
            PI3K/Akt signaling. These GT1b-rich exosomes function as <strong>DAMPs</strong> (Damage-Associated 
            Molecular Patterns), priming microglia and astrocytes for inflammation. This creates a 
            "pre-inflammatory" environment in the hypothalamus that amplifies the autoimmune response.
          </p>
        </div>

        <h2>The Complete Pathogenesis Cascade</h2>
        <p>
          Integrating all components, we can reconstruct the complete 8-step cascade from genetic 
          predisposition to orexin neuron destruction:
        </p>

        <figure class="my-8">
          <img 
            src="/images/narcolepsy-pathogenesis-cascade.svg" 
            alt="Complete 8-step pathogenesis cascade from genetic predisposition to narcolepsy"
            class="w-full rounded-lg border border-slate-700 shadow-lg"
          />
          <figcaption class="text-sm text-slate-600 mt-3 text-center">
            <strong>The Complete Pathogenesis Cascade:</strong> From inherited haplotype (Step 1) through 
            NEU1-driven hyperactivation (Step 3), B3GALT4-driven exosome shedding (Step 5), and finally 
            blood-brain barrier breach leading to orexin neuron destruction (Step 8).
          </figcaption>
        </figure>

        <h3>Clinical Implications of the Model</h3>
        <div class="grid md:grid-cols-3 gap-4 my-6">
          <div class="bg-blue-50 border border-blue-200 rounded-lg p-4">
            <h4 class="font-bold text-blue-800 mb-2">Biomarkers</h4>
            <ul class="text-blue-700 text-sm space-y-1">
              <li>‚Ä¢ Plasma GT1b-exosome levels</li>
              <li>‚Ä¢ Monocyte sialidase activity</li>
              <li>‚Ä¢ Pre-symptomatic risk identification</li>
            </ul>
          </div>
          <div class="bg-green-50 border border-green-200 rounded-lg p-4">
            <h4 class="font-bold text-green-800 mb-2">Potential Therapy</h4>
            <ul class="text-green-700 text-sm space-y-1">
              <li>‚Ä¢ NEU1 inhibitors (specific sialidase blockers)</li>
              <li>‚Ä¢ GT1b-exosome absorption</li>
              <li>‚Ä¢ TLR2/TLR4 antagonists</li>
            </ul>
          </div>
          <div class="bg-purple-50 border border-purple-200 rounded-lg p-4">
            <h4 class="font-bold text-purple-800 mb-2">Prevention</h4>
            <ul class="text-purple-700 text-sm space-y-1">
              <li>‚Ä¢ Pre-vaccination genetic screening</li>
              <li>‚Ä¢ Risk haplotype identification</li>
              <li>‚Ä¢ Personalized vaccine protocols</li>
            </ul>
          </div>
        </div>

        <!-- Critical Clarification: B3GALT4 and N-Glycans -->
        <h2>Critical Clarification: Gangliosides vs. N-Glycans</h2>
        
        <div class="warning-box">
          <h4 class="font-bold text-amber-800 mb-2">Important Biochemical Distinction</h4>
          <p class="text-amber-700 text-sm mb-2">
            NT1 patients show a <strong>3-fold increase in trisialylated N-glycans</strong> (HexNAc5Hex6NeuAc3) in serum. 
            It's tempting to attribute this to B3GALT4 (which is in the HLA region), but this is <strong>biochemically incorrect</strong>:
          </p>
          <ul class="text-amber-700 text-sm mb-0 space-y-1">
            <li>‚Ä¢ <strong>B3GALT4</strong> = GANGLIOSIDE-specific enzyme (creates GM1, GD1b)</li>
            <li>‚Ä¢ <strong>N-glycans</strong> = Built by completely different enzymes (MGAT5, B4GALT1, ST6GAL1)</li>
            <li>‚Ä¢ These N-glycan enzymes are on <strong>different chromosomes</strong> ‚Äî NOT linked to HLA</li>
          </ul>
        </div>

        <h3>The Real Driver: NEU1 (Catabolism, Not Anabolism)</h3>
        <p>
          The hypersialylation seen in NT1 is NOT due to increased synthesis, but rather <strong>decreased degradation</strong>. 
          NEU1 (neuraminidase 1) ‚Äî which IS in the HLA region ‚Äî removes sialic acids from glycoproteins:
        </p>
        <ul>
          <li>If NEU1 is underactive ‚Üí sialic acids accumulate ‚Üí hypersialylation</li>
          <li>This explains the N-glycan profile WITHOUT invoking B3GALT4</li>
          <li>NEU1 variants in LD with HLA-DQB1*06:02 are the likely cause</li>
        </ul>

        <h3>N-Glycan Synthesis Enzymes ‚Äî Chromosomal Map</h3>
        <p>
          The enzymes that build tri-antennary, trisialylated N-glycans are spread across the genome:
        </p>
        <table class="w-full text-sm my-6">
          <thead>
            <tr class="border-b bg-slate-50">
              <th class="text-left py-2 px-2">Enzyme</th>
              <th class="text-left py-2 px-2">Gene</th>
              <th class="text-left py-2 px-2">Chromosome</th>
              <th class="text-left py-2 px-2">Function</th>
            </tr>
          </thead>
          <tbody>
            <tr class="border-b">
              <td class="py-2 px-2">GnT-V</td>
              <td class="py-2 px-2"><span class="gene-name">MGAT5</span></td>
              <td class="py-2 px-2">2q21.2</td>
              <td class="py-2 px-2">Creates 3rd branch (tri-antennary)</td>
            </tr>
            <tr class="border-b">
              <td class="py-2 px-2">Œ≤4GalT1</td>
              <td class="py-2 px-2"><span class="gene-name">B4GALT1</span></td>
              <td class="py-2 px-2">9p13</td>
              <td class="py-2 px-2">Extends branches with galactose</td>
            </tr>
            <tr class="border-b">
              <td class="py-2 px-2">ST6Gal1</td>
              <td class="py-2 px-2"><span class="gene-name">ST6GAL1</span></td>
              <td class="py-2 px-2">3q27.3</td>
              <td class="py-2 px-2">Adds Œ±2-6 sialic acid (terminal cap)</td>
            </tr>
            <tr class="border-b bg-cyan-50">
              <td class="py-2 px-2">Sialidase</td>
              <td class="py-2 px-2"><span class="gene-name">NEU1</span></td>
              <td class="py-2 px-2 font-bold text-cyan-700">6p21.33 ‚ö†Ô∏è</td>
              <td class="py-2 px-2"><strong>REMOVES sialic acids</strong> ‚Äî in MHC region!</td>
            </tr>
          </tbody>
        </table>

        <div class="key-concept">
          <div class="key-concept-title">The Dual Pathway Model</div>
          <p class="mb-2">
            The narcolepsy risk haplotype affects <strong>two parallel pathways</strong>:
          </p>
          <div class="grid md:grid-cols-2 gap-4">
            <div class="bg-amber-50 border border-amber-200 rounded p-3">
              <h5 class="font-bold text-amber-800 mb-1">Ganglioside Pathway</h5>
              <p class="text-amber-700 text-sm mb-0">
                B3GALT4 ‚Üí ‚ÜëGT1b ‚Üí viral binding sites ‚Üí neuroinvasion
              </p>
            </div>
            <div class="bg-cyan-50 border border-cyan-200 rounded p-3">
              <h5 class="font-bold text-cyan-800 mb-1">N-Glycan Pathway</h5>
              <p class="text-cyan-700 text-sm mb-0">
                NEU1 ‚Üí ‚Üìsialic acid removal ‚Üí hypersialylation ‚Üí immune dysregulation
              </p>
            </div>
          </div>
        </div>

        <h2>Complete GT1b Biosynthesis Pathway ‚Äî Genetic Map</h2>
        <p>
          The enzymes required to synthesize GT1b are distributed across multiple chromosomes:
        </p>
        <table class="w-full text-sm">
          <thead>
            <tr class="border-b">
              <th class="text-left py-2">Gene</th>
              <th class="text-left py-2">Chromosome</th>
              <th class="text-left py-2">Reaction</th>
            </tr>
          </thead>
          <tbody>
            <tr class="border-b">
              <td class="py-2"><span class="gene-name">ST3GAL5</span></td>
              <td class="py-2">2p11.2</td>
              <td class="py-2">LacCer ‚Üí GM3 (initiates pathway)</td>
            </tr>
            <tr class="border-b">
              <td class="py-2"><span class="gene-name">ST8SIA1</span></td>
              <td class="py-2">12p12.1</td>
              <td class="py-2">GM3 ‚Üí GD3 (creates b-series)</td>
            </tr>
            <tr class="border-b">
              <td class="py-2"><span class="gene-name">B4GALNT1</span></td>
              <td class="py-2">12q13.3</td>
              <td class="py-2">GD3 ‚Üí GD2</td>
            </tr>
            <tr class="border-b bg-amber-50">
              <td class="py-2"><span class="gene-name">B3GALT4</span></td>
              <td class="py-2 font-bold text-red-700">6p21.32 ‚ö†Ô∏è</td>
              <td class="py-2"><strong>GD2 ‚Üí GD1b</strong> (in HLA region!)</td>
            </tr>
            <tr class="border-b">
              <td class="py-2"><span class="gene-name">ST3GAL2</span></td>
              <td class="py-2">16q22.1</td>
              <td class="py-2">GD1b ‚Üí GT1b (final step)</td>
            </tr>
          </tbody>
        </table>

        <h2>Proposed Mechanism ‚Äî Revised</h2>
        <p>
          The B3GALT4 discovery suggests a refined mechanism:
        </p>
        <ol>
          <li>
            <strong>Genetic susceptibility:</strong> Individuals with HLA-DQB1*06:02 carry a 
            linked B3GALT4 variant that increases GD1b/GT1b production
          </li>
          <li>
            <strong>Elevated GT1b:</strong> Higher GT1b levels on nerve terminal membranes 
            enhance binding and uptake of GT1b-binding molecules
          </li>
          <li>
            <strong>Enhanced transport:</strong> Vaccine antigens with GT1b affinity are 
            transported more efficiently to the spinal cord
          </li>
          <li>
            <strong>Autoimmune trigger:</strong> Antigens released in lamina I trigger 
            autoimmune response against orexin neurons
          </li>
          <li>
            <strong>HLA contribution:</strong> DQB1*06:02 may still contribute by efficiently 
            presenting the cross-reactive epitopes ‚Äî but it's secondary to the transport mechanism
          </li>
        </ol>

        <div class="info-box">
          <h4 class="font-bold text-blue-800 mb-2">Critical Research Questions</h4>
          <ul class="text-blue-700 text-sm mb-0 space-y-1">
            <li>‚Ä¢ Are B3GALT4 expression levels elevated in DQB1*06:02 carriers?</li>
            <li>‚Ä¢ Do narcolepsy patients have higher GT1b levels in peripheral nerves?</li>
            <li>‚Ä¢ Are there specific B3GALT4 SNPs in linkage disequilibrium with DQB1*06:02?</li>
            <li>‚Ä¢ Can B3GALT4 variants alone (without DQB1*06:02) confer susceptibility?</li>
          </ul>
        </div>

        <h2>The Missing Disease ‚Äî Why GT1b Variants Go Undetected</h2>
        <p>
          A striking observation: while there are well-characterized storage diseases for most gangliosides, 
          <strong>there is no known disease caused by primary accumulation of GD1b or GT1b</strong>.
        </p>
        
        <table class="w-full text-sm my-6">
          <thead>
            <tr class="border-b bg-slate-50">
              <th class="text-left py-2 px-2">Ganglioside</th>
              <th class="text-left py-2 px-2">Accumulation Disease</th>
              <th class="text-left py-2 px-2">Enzyme Defect</th>
            </tr>
          </thead>
          <tbody>
            <tr class="border-b">
              <td class="py-2 px-2">GM1</td>
              <td class="py-2 px-2">GM1 gangliosidosis</td>
              <td class="py-2 px-2">Œ≤-Galactosidase (GLB1)</td>
            </tr>
            <tr class="border-b">
              <td class="py-2 px-2">GM2</td>
              <td class="py-2 px-2">Tay-Sachs, Sandhoff disease</td>
              <td class="py-2 px-2">Hexosaminidase A/B</td>
            </tr>
            <tr class="border-b">
              <td class="py-2 px-2">GM3</td>
              <td class="py-2 px-2">GM3 synthase deficiency</td>
              <td class="py-2 px-2">ST3GAL5</td>
            </tr>
            <tr class="border-b bg-amber-50">
              <td class="py-2 px-2 font-bold">GD1b</td>
              <td class="py-2 px-2 text-slate-400 italic">None known</td>
              <td class="py-2 px-2">‚Äî</td>
            </tr>
            <tr class="border-b bg-amber-50">
              <td class="py-2 px-2 font-bold">GT1b</td>
              <td class="py-2 px-2 text-slate-400 italic">None known</td>
              <td class="py-2 px-2">‚Äî</td>
            </tr>
          </tbody>
        </table>

        <div class="key-concept">
          <div class="key-concept-title">Why No GT1b Storage Disease?</div>
          <p>
            The answer lies in the <strong>shedding mechanism</strong>. B-series gangliosides (GD1b, GT1b, GQ1b) 
            are exported from neurons via <strong>extracellular vesicles (EVs/exosomes)</strong>. This 
            ceramide-dependent budding process acts as a "bypass" of normal lysosomal degradation:
          </p>
          <ul class="mt-2 mb-0 text-sm">
            <li>A-series (GM1, GM2): Low shedding ‚Üí lysosomal accumulation ‚Üí storage diseases</li>
            <li>B-series (GT1b, GQ1b): High shedding ‚Üí extracellular export ‚Üí <strong>no storage disease</strong></li>
          </ul>
          <p class="mt-2 mb-0 text-sm">
            However, this shedding <em>increases immune exposure</em> ‚Äî glycan epitopes on shed EVs are 
            accessible to antibodies, explaining autoimmune syndromes like Miller Fisher (anti-GQ1b).
          </p>
        </div>

        <h3>Implications for the Hypothesis</h3>
        <p>
          This "invisible phenotype" has profound implications:
        </p>
        <ol>
          <li>
            <strong>No clinical flag:</strong> Individuals with B3GALT4 variants that increase GT1b 
            production would have no apparent disease ‚Äî the excess GT1b is simply released extracellularly.
          </li>
          <li>
            <strong>Hidden susceptibility:</strong> The only "symptom" would be increased vulnerability 
            to GT1b-mediated pathogen transport ‚Äî which would only manifest if exposed to the right trigger.
          </li>
          <li>
            <strong>The HLA paradox explained:</strong> This explains why HLA-DQB1*06:02 carriers have 
            no other phenotype besides narcolepsy susceptibility ‚Äî the linked B3GALT4 variant affects 
            only extracellular GT1b release, not intracellular storage.
          </li>
          <li>
            <strong>Population frequency:</strong> Because there's no selective pressure against GT1b 
            accumulation variants, they may be relatively common in the population.
          </li>
        </ol>

        <div class="warning-box">
          <h4 class="font-bold text-amber-800 mb-2">The Tetanus Toxin Parallel</h4>
          <p class="text-amber-700 text-sm mb-0">
            Unpublished research showed that tetanus toxin (GT1b-binding) is released extraneuronally 
            in the spinal cord, while cholera toxin (GM1-binding) remains confined to nerve terminals. 
            This differential behavior suggests GT1b has a unique "export" function that other 
            gangliosides lack ‚Äî explaining both why GT1b doesn't cause storage disease AND why 
            GT1b-binding antigens can trigger autoimmune responses in the CNS.
          </p>
        </div>

      </div>
    </div>
  </section>
</BaseLayout>
